Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 1.00 |
| ▸ | ICAM1 | P05362 | 20/20 | 1.00 |
| ▸ | ITGAL | P20701 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13817247 | 1.00 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL4018223 | 1.00 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL14019343 | 0.90 | ITGB2 (0.81) | ITGB2ICAM1ITGAL | |
| SCHEMBL13817322 | 0.89 | ITGB2 (0.80) | ITGB2ICAM1ITGAL | |
| SCHEMBL13817154 | 0.88 | ITGB2 (0.79) | ITGB2ICAM1ITGAL | |
| SCHEMBL13817090 | 0.87 | ITGB2 (0.77) | ITGB2ICAM1ITGAL | |
| SCHEMBL13817170 | 0.87 | ITGB2 (0.77) | ITGB2ICAM1ITGAL | |
| SCHEMBL5000918 | 0.86 | ITGB2 (0.75) | ITGB2ICAM1ITGAL | |
| SCHEMBL13817298 | 0.86 | ITGB2 (0.75) | ITGB2ICAM1ITGAL | |
| SCHEMBL13817120 | 0.86 | ITGAL (0.75) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589115-B2 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-sulfonylamino]-propionamide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7550494-B2 | Small molecules useful in the treatment of inflammatory disease | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550494-B2 | Small molecules useful in the treatment of inflammatory disease | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7517897-B2 | Derivatives of 6,7-dihydro-5h -imidazo[1,2-a] imidazole-3-sulfonic acid | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-14 | — | — | US | disclosed |
| US-20090088571-A1 | Synthesis of 6,7-Dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-02 | — | — | US | disclosed |
| US-7470795-B2 | Synthesis of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1216247-B1 | IMIDAZOIMIDAZOLES AND TRIAZOLES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080090819-A1 | DERIVATIVES OF [6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-SULFONYLAMINO]-PROPIONAMIDE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7345074-B2 | Derivatives of [6,7-dihydro-5H-imidazol[1,2-a]imidazole-3-sulfonylamino]-propionamide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7304067-B2 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060264472-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a] IMIDAZOLE-3-SULFONIC ACID | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-23 | — | — | US | disclosed |
| EP-1560830-B1 | DERIVATIVES OF [6, 7-DIHYDRO-5H-IMIDAZO[1,2 - A]IMIDAZOLE -3 -SULFONYLAMINO]-PROPIONAMIDE AND THEIR USE AS INHIBITORS UPON THE INTERACTION OF CAMS AND LEUKOINTEGRINS | BOEHRINGER INGELHEIM PHARMA (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1712553-A2 | Derivates of [6, 7-dihydro - 5H - imidazo[1,2- alpha]imidazole-3-sulfonylamino]-propionamide and their use as inhibitors upon the interaction of CAMS and leukointegrins | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20060025447-A1 | Synthesis of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
| US-20050165027-A1 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-07-28 | — | — | US | disclosed |
| US-20050054703-A1 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | US | disclosed |
| US-6844360-B2 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040127534-A1 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025447-A1 | Synthesis of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides | ICAM1, CD14, VCAM1 | ITGB2 125/4885ICAM1 1/4885ITGAL 33/4885 |
| US-20040127534-A1 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide | ARG1, ARG2, HPGDS | ITGB2 138/4885ICAM1 4/4885ITGAL 25/4885 |
| US-20080090819-A1 | DERIVATIVES OF [6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-SULFONYLAMINO]-PROPIONAMIDE | HPGDS, PTGIS, API5 | ITGB2 278/4885ICAM1 8/4885ITGAL 40/4885 |
| US-20060264472-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a] IMIDAZOLE-3-SULFONIC ACID | HPGDS, ICAM1, HCLS1 | ITGB2 442/4885ICAM1 2/4885ITGAL 96/4885 |
| US-20090088571-A1 | Synthesis of 6,7-Dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides | ICAM1, CD14, VCAM1 | ITGB2 125/4885ICAM1 1/4885ITGAL 33/4885 |
| US-20050054703-A1 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide | HPGDS, PTGIS, API5 | ITGB2 278/4885ICAM1 8/4885ITGAL 40/4885 |
| US-20050165027-A1 | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide | HPGDS, PTGIS, API5 | ITGB2 278/4885ICAM1 8/4885ITGAL 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.